Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carvedilol phosphate
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carvedilol phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity. It is a controlled-release formulation developed by GSK utilizing Avadel Pharmaceuticals' technology. The drug works by blocking both alpha-1 adrenergic receptors and beta adrenergic receptors, which helps reduce blood pressure and cardiac workload.
- Brand names
- Coreg CRCoreg CR MicropumpCOREG MR
- Other names
- Carvedilol phosphateCarvedilol phosphate hemihydrateCarvedilol dihydrogen phosphate hemihydrate
02
Targets
ADRA1A (α1A)ADRA2A (α2A)ADRB2 (β2)ABCB1 (P-glycoprotein)ADRB1 (β1)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on carvedilol phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carvedilol phosphate.